

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Advanced renal cell carcinoma (RCC)
 - a. 18 years of age or older
2. Hepatocellular carcinoma (HCC) previously treated with Nexavar (sorafenib)
 - a. 18 years of age or older
3. Locally advanced or metastatic differentiated thyroid cancer (DTC)
 - a. 12 years of age or older
 - b. Disease has progressed following prior VEGF-targeted therapy
 - c. Radioactive iodine-refractory or ineligible
4. Non-small cell lung cancer
 - a. 18 years of age or older
5. Locally advanced or metastatic pancreatic neuroendocrine tumor (pNET)
OR locally advanced or metastatic extra-pancreatic neuroendocrine tumor (epNET)
 - a. 12 years of age or older
 - b. Tumor is well-differentiated
 - c. Tumor is previously treated and unresectable

AND ALL of the following:

- a. **NO** recent history of severe hemorrhage
- b. Prescriber agrees to discontinue if the patient has uncontrolled GI perforations or fistulas
- c. Prescriber agrees to withhold the medication if intolerable palmar-plantar erythrodysesthesia (hand-foot syndrome) Grade 2 or 3 occurs, until improvement to Grade 1
- d. **NO** uncontrolled severe hypertension
- e. Prescriber agrees to discontinue if the patient develops reversible posterior leukoencephalopathy syndrome or nephrotic syndrome
- f. Prescriber agrees to discontinue if the patient develops an acute myocardial infarction or any other venous or arterial thromboembolic complication



- g. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Cabometyx and for 4 months after the last dose

Prior - Approval Limits

Quantity

Strength	Quantity
20 mg	90 tablets per 90 days
40 mg	
60 mg	

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Advanced renal cell carcinoma (RCC)
 - a. 18 years of age or older
2. Hepatocellular carcinoma (HCC)
 - a. 18 years of age or older
3. Locally advanced or metastatic differentiated thyroid cancer (DTC)
 - a. 12 years of age or older
4. Non-small cell lung cancer
 - a. 18 years of age or older
5. Locally advanced or metastatic pancreatic neuroendocrine tumor (pNET)
OR locally advanced or metastatic extra-pancreatic neuroendocrine tumor (epNET)
 - a. 12 years of age or older

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Cabometyx and for 4 months after the last dose

AND NONE of the following:

- a. Severe hemorrhage



**BlueCross
BlueShield**

Federal Employee Program.

**CABOMETYX
(cabozantinib)**

- b. Unmanaged gastrointestinal perforations or fistulas
- c. Palmar-plantar erythrodysesthesia (hand-foot syndrome) Grade 2 or 3
- d. Uncontrolled severe hypertension
- e. Reversible posterior leukoencephalopathy syndrome
- f. Acute myocardial infarction or any other venous or arterial thromboembolic complication
- g. Nephrotic syndrome

Prior - Approval *Renewal* Limits

Same as above